Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now
TNDM's global expansion and strategic integrations fuel growth potential, even as pump reliance and macro pressures weigh on performance.
Tandem Diabetes Care, Inc. (TNDM) Q3 2025 Earnings Call Transcript
Tandem Diabetes Care, Inc. ( TNDM ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Susan Morrison - Executive VP & Chief Administrative Officer John Sheridan - President, CEO & Director Leigh Vosseller - Executive VP, CFO & Treasurer Conference Call Participants Matthew Miksic - Barclays Bank PLC, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Christopher Pasquale - Nephron Research LLC Danielle Antalffy - UBS Investment Bank, Research Division Michael Kratky - Leerink Partners LLC, Research Division Joanne Wuensch - Citigroup Inc. Exchange Research Suraj Kalia - Oppenheimer & Co. Inc., Research Division William Plovanic - Canaccord Genuity Corp., Research Division Michael Polark - Wolfe Research, LLC Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Stephanie Piazzola - BofA Securities, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, and thank you for standing by.
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.31 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.
Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Tandem Diabetes Care (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up
Tandem Diabetes posts record Q2 sales and higher margins, but earnings miss sends shares tumbling 20%.
Tandem Diabetes Care: An Earnings Miss Confirms The Bear Case - Downgrade To Sell
Downgrading Tandem Diabetes Care to sell after Q2 2025 earnings confirms core U.S. business weakness and deteriorating profitability. Intense competition from Insulet and Medtronic is eroding Tandem's market share, with rivals showing stronger growth and profitability. Management's credibility is under pressure, due to material guidance downgrades and reactive strategy, despite upcoming product catalysts.
Tandem Diabetes Care, Inc. (TNDM) Q2 2025 Earnings Call Transcript
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants John F. Sheridan - President, CEO & Director Leigh A.
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Tandem Diabetes Care (TNDM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Beats Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.47 per share a year ago.
Bears are Losing Control Over Tandem Diabetes Care (TNDM), Here's Why It's a 'Buy' Now
Tandem Diabetes Care (TNDM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: Should You Buy?
Tandem Diabetes Care (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
